Are there ethnic differences in brain amyloid and tau in the seventh decade of life?
Are there ethnic differences in brain amyloid and tau in the seventh decade of life?
批准号:
9383870
负责人:
Jose Alejandro Luchsinger
金额:
$153.7万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2022-04-30
关键词:
AddressAgeAge-YearsAlzheimer&aposs DiseaseAmyloidAmyloid beta-ProteinAttenuatedBiological MarkersBiologyBlood VesselsBrainBrain imagingCerebrovascular DisordersClinical MarkersCognitionCommunitiesDataDatabasesDementiaDiabetes MellitusElderlyEthnic OriginEthnic groupFundingGoalsHigh PrevalenceHispanicsHyperglycemiaHypertensionInfarctionInferiorKnowledgeLifeLiteratureMagnetic Resonance ImagingMedialMediatingMemoryMemory impairmentNon-Insulin-Dependent Diabetes MellitusNot Hispanic or LatinoObesityOutcomePathway AnalysisPerformancePositron-Emission TomographyPrediabetes syndromeReportingRiskRisk FactorsTemporal LobeTimeTranslatingWhite Matter Hyperintensityage groupagedbasecritical periodethnic differenceethnic disparityethnic minority populationgenetic risk factorhealth datahigh riskin vivoliteracymiddle ageneuroimagingneuropathologyracial differencesexsocial health determinantstau Proteins
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Our goal is to examine whether ethnic and racial differences in brain amyloid β (Aβ) and tau, the major
neuropathology components of Alzheimer’s disease (AD), explain reported ethnic disparities in dementia of the
Alzheimer’s type (DAT) in Northern Manhattan We will examine ethnic differences in brain Aβ and tau,
ascertained in-vivo with positron emission tomography (PET), among Hispanics, Non-Hispanic Blacks (Blacks),
and Non-Hispanic Whites (Whites) aged 60 to 69 years from Northern Manhattan. We will also explore whether
ethnic differences in brain Aβ and tau explain ethnic differences in memory performance, the earliest clinical
marker of AD; whether ethnicity modifies the relation of APOE-ε4 and brain Aβ; whether ethnic disparities in
literacy and cerebrovascular disease (CVD) moderate the association of brain Aβ and tau with memory
performance. Lastly, we will explore whether the higher risk of DAT attributable to hyperglycemia (pre-diabetes
and type 2 diabetes) among Blacks and Hispanics compared with Whites is explained by higher brain Aβ and
tau. The risk of DAT is higher in elderly Blacks and Hispanics in Northern Manhattan compared with Whites. It
is unknown whether this disparity is due to differences in AD neuropathology, CVD, CVD risk factors, or social
determinants of health (SDOH). There is a paucity of studies of AD biomarkers in Blacks and Hispanics to answer
this question, particularly in late middle age. We propose to address these gaps in knowledge taking advantage
of an ongoing funded study of Aβ and tau PET (1R01AG050440, 3R01AG050440-02S1;09/01/15-05/31/20) in
100 Hispanics between 60 and 69 years of age at the time of brain imaging, a critical period for accumulation of
AD neuropathology. We propose to extend this funded project to 100 Blacks and Whites aged 60 to 69 years
from the same community in order to compare brain Aβ, tau, CVD, and cognition among Blacks, Hispanics and
Whites in this understudied age group. We will ascertain brain Aβ using 18F-Florbetaben PET, and tau using 18F-
THK-5351 PET at 2 time points 24 months apart. We will also conduct brain magnetic resonance imaging (MRI)
for co-registration of PET and for ascertainment of CVD (white matter hyperintensities and infarcts). Our primary
aim is to examine whether there are ethnic differences in the presence of whole brain fibrillar Aβ, and tau in
medial temporal and inferior temporal cortex, cross-sectionally and longitudinally, among Blacks, Hispanics and
Whites aged 60 to 69 years from the community of Northern Manhattan. We will also explore across and within
ethnic groups the association of whole brain fibrillar Aβ, and tau in medial temporal and inferior temporal cortex,
with memory performance, and moderation of this association by CVD and literacy. Secondary aim 1 is to
compare the association of APOE-ε4 with whole brain fibrillar Aβ and tau across ethnic groups cross sectionally
and longitudinally. Secondary aim 2 is to explore if ethnic disparities in hyperglycemia explain ethnic differences
in whole brain fibrillar Aβ, and tau in medial temporal and inferior temporal cortex and memory impairment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10507629
-
项目类别:
-
资助金额:$200.29万
-
财政年份:2022
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Midcareer Award for Research in Dementia Risk Factors and Prevention
-
批准号:10645176
-
项目类别:
-
资助金额:$12.13万
-
财政年份:2022
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
DPPOS AD/ADRD Health Economics Evaluation
-
批准号:10702144
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2022
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Alzheimer's Disease and Alzheimer's Disease Related Dementias in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Outcomes Study AD/ADRD Project
-
批准号:10901549
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2022
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Alzheimer's Disease and Alzheimer's Disease Related Dementias in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Outcomes Study AD/ADRD Project
-
批准号:10507628
-
项目类别:
-
资助金额:$1695.78万
-
财政年份:2022
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Association of cumulative exposure to metformin and other T2D medications with cognitive impairment and AD/ADRD biomarkers
-
批准号:10507636
-
项目类别:
-
资助金额:$8.15万
-
财政年份:2022
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Midcareer Award for Research in Dementia Risk Factors and Prevention
-
批准号:10457636
-
项目类别:
-
资助金额:$12.19万
-
财政年份:2022
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Measurement and estimation of lucidity prevalence in persons with dementia and neurological disorders
-
批准号:10091724
-
项目类别:
-
资助金额:$39.72万
-
财政年份:2020
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Measurement and estimation of lucidity prevalence in persons with dementia and neurological disorders
-
批准号:10688736
-
项目类别:
-
资助金额:$71.14万
-
财政年份:2020
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Pilot-Core
-
批准号:10237112
-
项目类别:
-
资助金额:$14.04万
-
财政年份:2020
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Pilot-Core
-
批准号:10668273
-
项目类别:
-
资助金额:$14.04万
-
财政年份:2020
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Measurement and estimation of lucidity prevalence in persons with dementia and neurological disorders
-
批准号:10864610
-
项目类别:
-
资助金额:$80.6万
-
财政年份:2020
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Metformin in Alzheimer's dementia Prevention (MAP)
-
批准号:10160752
-
项目类别:
-
资助金额:$959.75万
-
财政年份:2019
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Metformin in Alzheimer's dementia Prevention (MAP)
-
批准号:10418724
-
项目类别:
-
资助金额:$817.62万
-
财政年份:2019
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Metformin in Alzheimer's dementia Prevention (MAP)
-
批准号:10019760
-
项目类别:
-
资助金额:$8.11万
-
财政年份:2019
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Columbia Center for Interdisciplinary Research on Alzheimer's Disease Disparities (CIRAD)
-
批准号:9770755
-
项目类别:
-
资助金额:$69.09万
-
财政年份:2018
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Research Education Core
-
批准号:10451809
-
项目类别:
-
资助金额:$26.5万
-
财政年份:2018
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Columbia Center for Interdisciplinary Research on Alzheimer's Disease Disparities (CIRAD)
-
批准号:10451806
-
项目类别:
-
资助金额:$67.68万
-
财政年份:2018
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Research Education Core
-
批准号:10231025
-
项目类别:
-
资助金额:$26.54万
-
财政年份:2018
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
Columbia Center for Interdisciplinary Research on Alzheimer's Disease Disparities (CIRAD)
-
批准号:10231023
-
项目类别:
-
资助金额:$68.39万
-
财政年份:2018
-
负责人:Jose Alejandro Luchsinger
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: